Weight recurrence after Sleeve Gastrectomy versus Roux-en-Y gastric bypass

a propensity score matched nationwide analysis

Journal article (2023)

Authors

Erman O. Akpinar Dutch Institute for Clinical Auditing, Maastricht University Medical Center
Ronald S.L. Liem Dutch Obesity Clinic, Groene Hart Hospital
Simon W. Nienhuijs Catharina Hospital
Jan Willem M. Greve Maastricht University Medical Center, Zuyderland Medical Center, Dutch Obesity Clinic South
P.J. Marang-van de Mheen Leiden University Medical Center
P.J. Marang-van De Mheen Leiden University Medical Center
Perla J. Marang-Van De Mheen Leiden University Medical Center
P. J. Marang-van De Mheen Leiden University Medical Center
P. J. Marang-Van De Mheen Leiden University Medical Center
Perla J. Marang-van De Mheen Leiden University Medical Center
P. J. Marang-van de Mheen Leiden University Medical Center
Perla J. Marang-van de Mheen Leiden University Medical Center
P.J. Marang-Van De Mheen Leiden University Medical Center
Affiliation
External organisation
More Info
expand_more

Published Date

2023

Language

English

Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Affiliation

External organisation

Abstract

Background: Literature remains scarce on patients experiencing weight recurrence after initial adequate weight loss following primary bariatric surgery. Therefore, this study compared the extent of weight recurrence between patients who received a Sleeve Gastrectomy (SG) versus Roux-en-Y gastric bypass (RYGB) after adequate weight loss at 1-year follow-up. Methods: All patients undergoing primary RYGB or SG between 2015 and 2018 were selected from the Dutch Audit for Treatment of Obesity. Inclusion criteria were achieving ≥ 20% total weight loss (TWL) at 1-year and having at least one subsequent follow-up visit. The primary outcome was ≥ 10% weight recurrence (WR) at the last recorded follow-up between 2 and 5 years, after ≥ 20% TWL at 1-year follow-up. Secondary outcomes included remission of comorbidities at last recorded follow-up. A propensity score matched logistic regression analysis was used to estimate the difference between RYGB and SG. Results: A total of 19.762 patients were included, 14.982 RYGB and 4.780 SG patients. After matching 4.693 patients from each group, patients undergoing SG had a higher likelihood on WR up to 5-year follow-up compared with RYGB [OR 2.07, 95% CI (1.89–2.27), p < 0.01] and less often remission of type 2 diabetes [OR 0.69, 95% CI (0.56–0.86), p < 0.01], hypertension (HTN) [OR 0.75, 95% CI (0.65–0.87), p < 0.01], dyslipidemia [OR 0.44, 95% CI (0.36–0.54), p < 0.01], gastroesophageal reflux [OR 0.25 95% CI (0.18–0.34), p < 0.01], and obstructive sleep apnea syndrome (OSAS) [OR 0.66, 95% CI (0.54–0.8), p < 0.01]. In subgroup analyses, patients who experienced WR after SG but maintained ≥ 20%TWL from starting weight, more often achieved HTN (44.7% vs 29.4%), dyslipidemia (38.3% vs 19.3%), and OSAS (54% vs 20.3%) remission compared with patients not maintaining ≥ 20%TWL. No such differences in comorbidity remission were found within RYGB patients. Conclusion: Patients undergoing SG are more likely to experience weight recurrence, and less likely to achieve comorbidity remission than patients undergoing RYGB.